Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy. - MarketWatch
1. Goldman Sachs lowered Moderna's rating from buy to neutral. 2. Moderna's revenue guidance for respiratory vaccines was cut again. 3. Analysts forecast $1.5 billion RSV vaccine revenue at low end. 4. Moderna is unlikely to be cash break-even until 2029. 5. Important trial data milestones are expected in 2025.